Clinical Trial Update: NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes

View source ↗

Summary

A Bayer-sponsored clinical trial is recruiting patients with advanced or recurrent solid tumors that harbor NTRK gene fusions to evaluate a targeted therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors Harboring Ntrk Gene Fusions

Snippet

Sponsor: Bayer | Conditions: Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion | Status: RECRUITING